Eric M Wohlford1, Peter F Huang2, Jennifer R Elhawary3, Lauren A Millette4, Maria G Contreras2, Jonathan Witonsky1, Cécile T J Holweg4, Sam S Oh2, Christine Lee5, Christine Merenda5, Ronald L Rabin6, Richardae Araojo5, Angel C Y Mak2, Celeste S Eng2, Donglei Hu2, Scott Huntsman2, Michael A LeNoir7, Jose R Rodríguez-Santana8, Luisa N Borrell9, Esteban G Burchard10. 1. Division of Pediatric Allergy and Immunology, University of California San Francisco, San Francisco, Calif; Department of Medicine, University of California San Francisco, San Francisco, Calif. 2. Department of Medicine, University of California San Francisco, San Francisco, Calif. 3. Department of Medicine, University of California San Francisco, San Francisco, Calif. Electronic address: jennifer.elhawary@ucsf.edu. 4. Genentech Inc, South San Francisco, Calif. 5. Office of Minority Health and Health Equity, US Food and Drug Administration, Silver Spring, Md. 6. Center for Biologics Evaluation and Research, US Food and Drug Administration, Silver Spring, Md. 7. Bay Area Pediatrics, Oakland, Calif. 8. Centro de Neumologia Pediátrica, Caguas, Puerto Rico. 9. Department of Epidemiology & Biostatistics, Graduate School of Public Health & Health Policy, City University of New York, New York, NY. 10. Department of Medicine, University of California San Francisco, San Francisco, Calif; Department of Bioengineering and Therapeutic Sciences, University of California San Francisco, San Francisco, Calif.
Abstract
BACKGROUND: Asthma is a heterogeneous disease. Clinical blood parameters differ by race/ethnicity and are used to distinguish asthma subtypes and inform therapies. Differences in subtypes may explain population-specific trends in asthma outcomes. However, these differences in racial/ethnic minority pediatric populations are unclear. OBJECTIVE: We investigated the association of blood parameters and asthma subtypes with asthma outcomes and examined population-specific eligibility for biologic therapies in minority pediatric populations. METHODS: Using data from 2 asthma case-control studies of pediatric minority populations, we performed case-control (N = 3738) and case-only (N = 2743) logistic regressions to quantify the association of blood parameters and asthma subtypes with asthma outcomes. Heterogeneity of these associations was tested using an interaction term between race/ethnicity and each exposure. Differences in therapeutic eligibility were investigated using chi-square tests. RESULTS: Race/ethnicity modified the association between total IgE and asthma exacerbations. Elevated IgE level was associated with worse asthma outcomes in Puerto Ricans. Allergic asthma was associated with worse outcomes in Mexican Americans, whereas eosinophilic asthma was associated with worse outcomes in Puerto Ricans. A lower proportion of Puerto Ricans met dosing criteria for allergic asthma-directed biologic therapy than other groups. A higher proportion of Puerto Ricans qualified for eosinophilic asthma-directed biologic therapy than African Americans. CONCLUSIONS: We found population-specific associations between blood parameters and asthma subtypes with asthma outcomes. Our findings suggest that eligibility for asthma biologic therapies differs across pediatric racial/ethnic populations. These findings call for more studies in diverse populations for equitable treatment of minority patients with asthma.
BACKGROUND: Asthma is a heterogeneous disease. Clinical blood parameters differ by race/ethnicity and are used to distinguish asthma subtypes and inform therapies. Differences in subtypes may explain population-specific trends in asthma outcomes. However, these differences in racial/ethnic minority pediatric populations are unclear. OBJECTIVE: We investigated the association of blood parameters and asthma subtypes with asthma outcomes and examined population-specific eligibility for biologic therapies in minority pediatric populations. METHODS: Using data from 2 asthma case-control studies of pediatric minority populations, we performed case-control (N = 3738) and case-only (N = 2743) logistic regressions to quantify the association of blood parameters and asthma subtypes with asthma outcomes. Heterogeneity of these associations was tested using an interaction term between race/ethnicity and each exposure. Differences in therapeutic eligibility were investigated using chi-square tests. RESULTS: Race/ethnicity modified the association between total IgE and asthma exacerbations. Elevated IgE level was associated with worse asthma outcomes in Puerto Ricans. Allergic asthma was associated with worse outcomes in Mexican Americans, whereas eosinophilic asthma was associated with worse outcomes in Puerto Ricans. A lower proportion of Puerto Ricans met dosing criteria for allergic asthma-directed biologic therapy than other groups. A higher proportion of Puerto Ricans qualified for eosinophilic asthma-directed biologic therapy than African Americans. CONCLUSIONS: We found population-specific associations between blood parameters and asthma subtypes with asthma outcomes. Our findings suggest that eligibility for asthma biologic therapies differs across pediatric racial/ethnic populations. These findings call for more studies in diverse populations for equitable treatment of minority patients with asthma.
Authors: Esteban González Burchard; Pedro C Avila; Sylvette Nazario; Jesus Casal; Alfonso Torres; Jose R Rodriguez-Santana; Monica Toscano; Jody Senter Sylvia; MariaElena Alioto; Michael Salazar; Ivan Gomez; Joanne K Fagan; Jorge Salas; Craig Lilly; Henry Matallana; Elad Ziv; Richard Castro; Moises Selman; Rocio Chapela; Dean Sheppard; Scott T Weiss; Jean G Ford; Homer A Boushey; William Rodriguez-Cintron; Jeffrey M Drazen; Edwin K Silverman Journal: Am J Respir Crit Care Med Date: 2003-11-14 Impact factor: 21.405
Authors: Carmen A Peralta; Yongmei Li; Christina Wassel; Shweta Choudhry; Walter Palmas; Michael F Seldin; Neil Risch; David Siscovick; Donna Arnett; Bruce Psaty; Michael G Shlipak Journal: Circ Cardiovasc Genet Date: 2010-05-05
Authors: X-Y Zhang; J L Simpson; H Powell; I A Yang; J W Upham; P N Reynolds; S Hodge; A L James; C Jenkins; M J Peters; J-T Lin; P G Gibson Journal: Clin Exp Allergy Date: 2014-09 Impact factor: 5.018
Authors: Lara J Akinbami; Jeanne E Moorman; Cathy Bailey; Hatice S Zahran; Michele King; Carol A Johnson; Xiang Liu Journal: NCHS Data Brief Date: 2012-05
Authors: Sally Wenzel; Linda Ford; David Pearlman; Sheldon Spector; Lawrence Sher; Franck Skobieranda; Lin Wang; Stephane Kirkesseli; Ross Rocklin; Brian Bock; Jennifer Hamilton; Jeffrey E Ming; Allen Radin; Neil Stahl; George D Yancopoulos; Neil Graham; Gianluca Pirozzi Journal: N Engl J Med Date: 2013-05-21 Impact factor: 91.245
Authors: Hermes Fundora-Hernández; Silvia J Venero-Fernández; Ramón Suárez-Medina; Esperanza de la C Mora-Faife; Gladys García-García; Ileana del Valle-Infante; Liem Gómez-Marrero; Andrea Venn; John Britton; Andrew W Fogarty Journal: Trop Med Int Health Date: 2014-03-28 Impact factor: 2.622
Authors: Christina J Jones; Priyamvada Paudyal; Robert M West; Adel H Mansur; Nicola Jay; Nick Makwana; Sarah Baker; Mamidipudi T Krishna Journal: Clin Exp Allergy Date: 2022-04-14 Impact factor: 5.401